Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.
JCO Oncol Pract. 2020 Mar 05;:JOP1900506
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol. 2020 Feb 04;:
EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis.
Blood Res. 2019 Dec;54(4):282-284
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Haematologica. 2020 Jan 02;:
A case of secondary acute myeloid leukemia on a background of glycogen storage disease with chronic neutropenia treated with granulocyte colony stimulating factor.
JIMD Rep. 2019 Sep;49(1):37-42
Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2019 Oct 02;2(10):e1912666
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Blood Adv. 2019 Aug 13;3(15):2307-2311
Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability.
Biol Blood Marrow Transplant. 2019 Jan 14;:
Biol Blood Marrow Transplant. 2019 Jan 06;: